Thomas Birger Edén-Jensen
Vice President & Head of External Supply Management Radiopharmaceuticals Bayer
As a seasoned manufacturing and supply chain professional with a passion for radiopharmaceuticals, I’ve spent over a decade optimizing operations and driving efficiency.
My journey began in the pharmaceutical industry, where I honed my skills in process development, technology transfer, Operation Excellence/LEAN and management. From there, I transitioned to radiopharmaceuticals, fascinated by their critical role in diagnostics and treatment, with focus on Clinical and Commercial production, and supply chain operations and CDMO oversight.
Thursday 17th September 2026
Designing Logistics Strategies Across Clinical Phases to Balance Cost, Reliability, & Patient Risk
9:00 am
- Comparing high-touch, premium logistics models used in early-phase trials with more standardized approaches required for late-stage and commercial distribution
- Managing the trade-off between cost optimization and guaranteed delivery when each patient dose carries significant clinical and financial value
- Implementing contingency strategies including overproduction, reallocation, and backup routing to mitigate disruption
- Transitioning logistics models from bespoke to scalable while maintaining delivery performance
Thursday 17th September 2026
Panel Discussion: Future Directions – Where Does the Chain Break? A Collective Assessment of the Industry’s Most Critical Unresolved Supply Chain Challenges & the Priorities That Must Be Addressed Collectively Before the Next Wave of Approvals Arrives
4:00 pm
- Across the two days, which single supply chain or manufacturing bottleneck has emerged as most urgent, and what does a credible industry-level response to it look like?
- Where does the field realistically stand on isotope supply security in five years, and which production pathways, technologies, and investment models will determine whether commercial-scale alpha therapy becomes a reality?
- How must the relationship between biopharma, CDMOs, isotope providers, logistics specialists, and clinical sites evolve structurally to one that can reliably deliver therapies to patients at scale?
